Research programme: cancer therapeutics - Ipsen

Drug Profile

Research programme: cancer therapeutics - Ipsen

Alternative Names: 17 beta hydroxysteroid dehydrogenase inhibitors - Ipsen; Cytotoxic-peptide conjugates - Ipsen; DASI - Ipsen; Dual aromatase-steroid sulfatase inhibitors - Ipsen; Prolactin receptor antagonists - Ipsen; SARD - Ipsen; Selective androgen receptor degraders - Ipsen; siRNA -peptide conjugates - Ipsen

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Ipsen
  • Class Antineoplastics; Peptides; Small interfering RNA
  • Mechanism of Action Androgen receptor degradation enhancers; Aromatase inhibitors; Estradiol dehydrogenase inhibitors; Prolactin receptor antagonists; RNA interference; Sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Oct 2016 Preclinical development is ongoing for Cancer in France (Ipsen pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
  • 31 Dec 2010 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top